Actively Recruiting
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Led by Samsung Medical Center · Updated on 2024-03-26
50
Participants Needed
1
Research Sites
197 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
CONDITIONS
Official Title
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- HER2 positive breast cancer
- Stage IV disease
- Treated with T-Dxd
- Available FFPE samples
You will not qualify if you...
- Triple-negative breast cancer (TNBC)
- Hormone receptor positive breast cancer
- No available FFPE samples
- Treatments other than T-Dxd
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ji-Yeon Kim
Seoul, South Korea, 06351
Actively Recruiting
Research Team
J
Ji-Yeon Kim
CONTACT
M
MIRYOUNG HONG
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here